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Abstract
Objective:  To  estimate  the  costs  of  hospitalization  in  premature  infants  exposed  or  not  to
antenatal corticosteroids  (ACS).
Method:  Retrospective  cohort  analysis  of  premature  infants  with  gestational  age  of  26--
32 weeks  without  congenital  malformations,  born  between  January  of  2006  and  December  of
2009 in  a  tertiary,  public  university  hospital.  Maternal  and  neonatal  demographic  data,  neona-
tal morbidities,  and  hospital  inpatient  services  during  the  hospitalization  were  collected.  The
costs were  analyzed  using  the  microcosting  technique.
Results:  Of  220  patients  that  met  the  inclusion  criteria,  211  (96%)  charts  were  reviewed:
170 newborns  received  at  least  one  dose  of  antenatal  corticosteroid  and  41  did  not  receive
the antenatal  medication.  There  was  a  14--37%  reduction  of  the  different  cost  components  in
infants exposed  to  ACS  when  the  entire  population  was  analyzed,  without  statistical  signiﬁ-
cance. Regarding  premature  infants  who  were  discharged  alive,  there  was  a  24--47%  reduction
of the  components  of  the  hospital  services  costs  for  the  ACS  group,  with  a  signiﬁcant  decrease
in the  length  of  stay  in  the  neonatal  intensive  care  unit  (NICU).  In  very-low  birth  weight  infants,
considering  only  the  survivors,  ACS  promoted  a  30--50%  reduction  of  all  elements  of  the  costs,
with a  36%  decrease  in  the  total  cost  (p  =  0.008).  The  survivors  with  gestational  age  <30  weeks
showed a  decrease  in  the  total  cost  of  38%  (p  =  0.008)  and  a  49%  reduction  of  NICU  length  of
stay (p  =  0.011).
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Conclusion:  ACS  reduces  the  costs  of  hospitalization  of  premature  infants  who  are  discharged
alive, especially  those  with  very  low  birth  weight  and  <30  weeks  of  gestational  age.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Custos  da  hospitalizac¸ão de  recém-nascidos  pré-termo:  impacto  da  corticoterapia
antenatal
Resumo
Objetivo:  Estimar  os  custos  da  internac¸ão  hospitalar  de  prematuros,  cujas  mães  receberam  ou
não corticoide  antenatal  (CEA).
Método:  Coorte  retrospectiva  de  prematuros  sem  malformac¸ões  congênitas  com  idade  gesta-
cional de  26  a  32  semanas,  nascidos  entre  janeiro/2006  e  dezembro/2009,  em  hospital  público,
terciário e  universitário  brasileiro.  Coletaram-se  dados  demográﬁcos  maternos  e  dos  recém-
nascidos (RN),  a  morbidade  neonatal  e  utilizac¸ão  de  recursos  de  saúde  durante  a  internac¸ão
hospitalar.  Os  custos  foram  analisados  pela  técnica  de  microcosting.
Resultados:  Dos  220  nascidos  que  obedeciam  a  critérios  de  inclusão,  211  (96%)  prontuários
foram revisados:  170  receberam  CEA  e  41  não  receberam  a  medicac¸ão.  Analisando-se  toda  a
populac¸ão, houve  reduc¸ão  de  14-37%  entre  os  diferentes  componentes  do  custo  nos  pacientes
expostos ao  CEA,  sem  signiﬁcância  estatística.  Na  análise  de  prematuros  que  receberam  alta
hospitalar  vivos,  o  grupo  com  CEA  teve  reduc¸ão  de  24-47%  nos  vários  componentes  dos  cus-
tos hospitalares,  com  diminuic¸ão  signiﬁcante  dos  dias  de  internac¸ão  em  terapia  intensiva.  Os
nascidos  com  peso  <1500  g,  considerando-se  somente  os  sobreviventes,  são  aqueles  que  mais
se beneﬁciaram  da  administrac¸ão  do  CEA,  com  reduc¸ão  signiﬁcante  de  todos  componentes  dos
custos em  30-50%,  sendo  tal  diminuic¸ão  de  36%  no  custo  total  (p  =  0,008).  Para  o  grupo  com
idade gestacional  <30  semanas,  também  sobreviventes,  houve  diminuic¸ão  do  custo  total  de  38%
(p =  0,008)  e  reduc¸ão  de  49%  dos  dias  de  internac¸ão  em  UTI  neonatal  (p  =  0,011).
Conclusões:  O  CEA  reduz  o  custo  hospitalar  de  prematuros  que  sobrevivem  à  internac¸ão  após
o parto,  principalmente  naqueles  abaixo  de  1500  g  e  30  semanas  de  idade  gestacional.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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aIntroduction
There  has  been  great  progress  in  reducing  child  mortality
in  the  last  two  decades.1,2 Since  1990,  the  global  neona-
tal  mortality  rate  was  reduced  by  37%,  from  33  to  21  deaths
per  1000  live  births,3 and  now  the  World  Health  Organization
(WHO),  with  the  Every  Newborn  program,  proposes  a  reduc-
tion  to  10  deaths  per  1000  live  births  until  the  year  2035.  For
this  goal  to  be  achieved,  it  will  be  necessary  to  increase  the
use  of  effective  interventions  to  reduce  the  leading  causes
of  neonatal  deaths,  particularly  prematurity.4
Antenatal  corticosteroids  (ACS)  participate  in  this  con-
text  as  one  of  the  proven  effective  interventions  to  reduce
complications  of  prematurity,  as  they  induce  fetal  maturity.5
In  2010,  a  systematic  review6 of  18  randomized  controlled
trials  involving  the  use  of  ACS  was  conducted  in  14  high-
income  countries  that  participated  in  the  meta-analysis  of
the  Cochrane  Library5 and  in  four  middle-income  coun-
tries,  including  Brazil.  While  the  Cochrane  meta-analysis
suggested  that  ACS  reduced  neonatal  mortality  by  31%,  the
new  review  showed  that  ACS  decreased  neonatal  mortality
by  53%  (RR  0.47;  95%  CI:  0.35--0.64)  and  neonatal  mor-
bidity  by  37%  (RR:  0.63;  95%  CI:  0.49--0.81).  It  is  believed
that,  in  low-income  countries  with  few  neonatal  intensive
care  resources,  the  beneﬁcial  effects  of  corticosteroids  in
e
n
(educing  neonatal  morbidity  and  mortality  could  be  even
reater.6
Data  on  the  use  of  ACS  in  Brazil  demonstrate  that  much
emains  to  be  done  to  increase  its  prescription  to  Brazilian
regnant  women.  The  Brazilian  Neonatal  Research  Network
nnual  report  in  2012,  involving  20  Brazilian  university  hos-
itals,  showed  low  use  of  ACS:  67%  of  pregnant  women
ho  gave  birth  to  preterm  infants  weighing  less  than  1500  g
eceived  the  antenatal  medication  (ranging  from  62%  to  75%
mong  the  centers).7
Among  preterm  infants  with  birth  weight  <1000  g,  a
ecent  study  in  the  Brazilian  population  demonstrated  that
wo  thirds  of  them  received  ACS.8 It  is  noteworthy  that
he  WHO  considers  ACS  as  a  priority  intervention  for  the
revention  of  prematurity  complications.9,10 It  is  unaccept-
ble  that  countries  with  high  rates  of  prematurity,  such  as
razil,  do  not  universally  use  ACS  for  risk  pregnancies,  which
emonstrates  missed  opportunities  to  increase  the  chance
f  survival  of  preterm  infants.
If  ACS  use  was  prevalent  in  Brazil,  there  could  be  a  reduc-
ion  in  morbidity  and  mortality  associated  with  prematurity
nd,  consequently,  in  hospital  costs.  In  1991,  Mugford  et  al.11stimated  that  the  administration  of  corticosteroids  to  preg-
ant  women  with  less  than  35  weeks  of  gestational  age
GA)  would  reduce  the  mean  costs  per  infant  by  10%,  with
2a
s
L
m
2
r
A
h
a
c
M
T
i
2
m
a
m
m
U
F
t
H
t
h
i
c
1
w
f
n
u
i
w
o
b
m
p
n
n
u
p
b
T
m
d
•
•
•
•
•
•
•6  
 14%  decrease  in  the  mean  cost  per  survivor.  In  another
tudy  involving  ACS  and  costs,  published  in  1995,  Simpson  &
ynch12 used  an  analytical  decision-making  model  and  esti-
ated  a  reduction  of  three  to  17  deaths  and  cost  savings  of
00,000  to  500,000  dollars  per  100  babies  exposed  to  ACS.
In  Brazil,  there  have  been  few  studies  involving  costs
elated  to  preterm  infants  whose  mothers  received  or  not
CS.  Therefore,  the  present  study  aimed  to  analyze  the
ospital  costs  of  hospitalization  of  preterm  infants  born  in
 Brazilian  public  university  hospital  exposed  to  antenatal
orticosteroids,  compared  to  those  who  were  not.
ethods
his  was  a  retrospective  analysis  of  a  cohort  of  preterm
nfants  born  between  January  of  2006  and  December  of
009,  after  it  was  approved  by  the  Research  Ethics  Com-
ittee  of  the  institution.  Preterm  infants  born  between  26
nd  32  weeks  GA,  as  determined  by  the  best  obstetric  esti-
ate,  were  included  in  the  analysis.  Infants  with  congenital
alformations  were  excluded.13
Data  were  collected  from  the  neonatal  unit  of  Hospital
niversitário  da  Escola  Paulista  de  Medicina--Universidade
ederal  de  São  Paulo,  a  tertiary  public  hospital  whose  neona-
al  unit  is  classiﬁed  as  Level  III  by  the  National  Register  of
ealthcare  Facilities  (Cadastro  Nacional  de  Estabelecimen-
os  de  Saúde  [CNES]).14 At  the  time  of  the  study,  the  unit
ad  eight  intensive  care  beds,  eight  conventional  neonatal
ntermediate  care  beds,  and  four  intermediate  kangaroo-
are  beds.  The  maternity  ward  treated  approximately
000  newborns  a  year,  and  is  specialized  in  pregnant  women
ith  severe  medical  or  obstetric  complications  and/or
etuses  with  clinical  diseases  or  malformations.  Of  the  total
umber  of  births,  30--40%  were  admitted  to  the  neonatal
nit  annually.
Maternal  demographic  data,  pregnancy  complications,
nformation  about  delivery,  and  neonatal  demographic  data
ere  collected  from  medical  records  of  newborns.  Data
n  ACS  administration  was  assessed,  considering  infants  as
elonging  to  the  group  exposed  to  corticosteroids  if  the
other  had  received  any  dose  of  the  medication  for  the
urpose  of  fetal  maturation.  Data  were  also  collected  on
eonatal  morbidity  and  days  of  hospitalization,  divided  into
eonatal  intensive  care  units  (NICUs)  and  intermediate  care
nits.
The  cost  analysis  was  conducted  using  the  microcosting
rocess,15 which  identiﬁes  and  measures  each  resource  used
y  assigning  them  values  and  integrating  this  information.
hus,  the  costs  were  divided  into  respiratory,  laboratory,
edication,  tests,  hospital  daily  rates,  and  total  costs,
eﬁned  as  follows:
 Respiratory  cost:  evaluation  of  mechanical  ventilation
time,  continuous  positive  airway  pressure  (CPAP),  and
inhaled  oxygen  therapy,  in  addition  to  the  need  for  and
number  of  surfactant  doses  administered.  The  estimated
respiratory  cost  was  based  on  the  maintenance  costs  of
mechanical  ventilators,  the  CPAP  circuit,  gas  consump-
tion  (oxygen)  by  the  mechanical  ventilation  equipment,
and  cubic  meter  of  oxygen.  Therefore,  a  daily  mechan-
ical  ventilation  rate  was  calculated,  as  well  as  that  of
s
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CPAP  and  oxygen  inhalation,  in  addition  to  the  cost  of  the
surfactant  dose,  using  the  drug  price  list  by  the  National
Health  Surveillance  Agency  (Agência  Nacional  de  Vigilân-
cia  Sanitária  [ANVISA]).16
 Laboratory  cost:  all  laboratory  tests  performed  during
hospitalization  and  costs  were  provided  by  the  central
laboratory  of  the  hospital.  Costs  of  tests  performed  at  the
unit,  such  as  glycemia  and  capillary  hematocrit,  were  also
estimated,  taking  into  account  only  the  cost  of  materials
provided  by  the  hospital’s  purchasing  department.
 Imaging  test  costs  and  others:  all  imaging  tests
(X-rays,  ultrasound,  computed  tomography  [CT],  mag-
netic  resonance  imaging  [MRI],  and  contrast  studies),
echocardiogram  and  electrocardiogram  (ECG),  fundus
examination,  otoacoustic  emissions,  and  neonatal  screen-
ing  for  inborn  errors  of  metabolism  were  considered.  The
costs  were  estimated  based  on  the  payment  system  of  the
Brazilian  Uniﬁed  Health  System  (Sistema  Único  de  Saúde
[SUS]).
 Nutritional  cost:  comprised  the  daily  neonatal  parenteral
nutrition  cost,  whose  value  was  provided  by  the  hospital
pharmacy,  as  well  as  the  cost  of  enteral  feeding,  calcu-
lated  with  the  help  of  the  Unit’s  nutritionist,  through  the
mean  consumption  of  preterm  and  term  infants  formula
and  the  market  price  of  the  formula.
 Cost  of  medications:  the  cost  of  the  materials  used
for  drug  administration,  whether  by  infusion  pump  or
direct  administration,  was  calculated.  It  was  also  veri-
ﬁed,  through  the  nursing  staff,  the  duration  of  antibiotics
and  drugs  reused  after  the  bottles  were  opened.  The  mean
cost  of  drugs  was  estimated  based  on  March  2013  ANVISA’s
price  list16 (conformity  list),  considering  the  maximum
selling  price  to  the  government.
 Hospital  daily  rates:  considering  the  rates  provided  by  the
hospital  accounting  department,  direct  costs  were  veri-
ﬁed  (wages)  at  the  cost  center  of  the  neonatal  unit  and
indirect  costs  (electricity,  water,  and  sewage  system),  as
well  as  the  costs  of  cleaning  and  ofﬁce  supplies  and  dis-
tribution  of  costs  from  other  hospital  sectors.
At  the  time  of  the  study,  the  team  had  54  nurses,  two  phys-
ical  therapists,  and  ﬁve  attending  physicians  who  were
included  in  the  hospital  cost  sheets.  As  for  the  other
members  of  the  medical  staff  (assistants,  professors,
and  residents)  and  other  professionals  (speech  therapists,
nutritionists,  pharmacists,  and  social  workers),  they  were
not  included  in  the  unit  cost  sheets,  as  they  were  employ-
ees  of  the  university.  Thus,  the  mean  costs  during  the
study  period  were  calculated  and  divided  by  the  number
of  patients  admitted  to  the  unit  in  the  same  period,  yield-
ing  a daily  cost  per  patient  of  USD  142.00.  To  calculate  this
cost  component,  the  number  of  hospitalization  days  was
multiplied  by  the  estimated  hospital  daily  rate.
 Total  cost:  comprised  the  respiratory  costs,  medications,
nutritional  costs,  and  laboratory  tests,  as  well  as  other
costs  with  blood  therapy,  phototherapy,  cost  of  catheters,
surgeries,  and  other  eventual  procedures,  in  addition  to
the  hospital  rates.Aiming  to  compare  the  study  results  with  international
tudies,  the  costs  were  converted  from  Brazilian  reals  to  US
ollars  at  an  exchange  rate  of  2.249  (mean  annual  rate  in
013).17
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Table  1  Maternal  demographic  characteristics  and  of  newborns  exposed  or  not  to  antenatal  corticosteroids  (ACS),  expressed
in number  (%)  or  mean  ±  standard  deviation.
With  ACS
n  =  170
Without  ACS
n  =  41
p
Maternal  age  in  years  29  ±  6  29  ±  8  0.870
N. of  prenatal  consultations  6  ±  3  5  ±  2  0.019
C-section birth  138  (81%)  20  (48%)  <0.001
Caucasian ethnicity 104  (61%) 19  (46%)  0.084
Primigravida 64  (37%) 12  (29%) 0.315
Hypertensive  syndromes 50  (29%) 11  (26%) 0.743
Male gender 83  (48%) 20  (48%) 0.996
Weight (grams)  1302  ±  360  1278  ±  473  0.766
Gestational age  (weeks)  30  ±  2  29  ±  2  0.231
SGA 36  (21%)  9  (22%)  0.916
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cSGA, small for gestational age.
For  the  statistical  analysis,  categorical  variables  were
expressed  by  the  number  and  frequency  of  each  event  in  the
study  groups,  and  compared  by  Pearson’s  chi-squared  test  or
Fisher’s  exact  test.  Numerical  variables  were  expressed  as
means  and  compared  by  Student’s  t-test  or  Mann--Whitney
test,  according  to  data  normality.  To  compare  the  clinical
outcomes  between  the  groups  with  and  without  ACS,  rel-
ative  risks  and  conﬁdence  intervals  were  calculated.  SPSS
(SPSS  Inc.  Released  2008.  SPSS  Statistics  for  Windows,  ver-
sion  17.0,  IL,  USA)  and  EPI  INFO  (Centers  for  Disease  Control
and  Prevention,  version  7,  GA,  USA)  were  used  for  the  sta-
tistical  analysis.  Signiﬁcance  level  was  set  at  0.05  for  all
tests.
Results
During  the  study  period,  220  neonates  between  26  and  32
completed  weeks  of  GA  met  the  inclusion  criteria.  Of  these,
nine  records  were  lost  and  211  (96%)  were  reviewed,  of
which  170  (80%)  received  at  least  one  dose  of  ACS  and  41
(20%)  did  not  receive  the  medication.  The  demographic  data
of  the  groups  are  shown  in  Table  1  and  those  related  to
neonatal  morbidity  are  shown  in  Table  2.
Table  3  shows  the  mean  hospital  costs  subdivided  among
its  main  components,  and  also  the  mean  days  of  hospitaliza-
tion  in  the  NICU  and  intermediate  care  unit  for  the  entire
study  population  and  for  the  survivors;  the  latter  were  sub-
divided  between  those  weighing  less  than  1000  g  and  1500  g
and  in  different  GA  ranges.  The  costs  of  all  the  components
increased  as  birth  weight  and  GA  decreased.  The  highest
cost  component  was  that  related  to  staff  salary,  here  encom-
passed  by  hospital  daily  rates.
Table  4  shows  the  costs  according  to  several  categories
of  the  analyzed  sample,  comparing  hospital  costs  among
newborns  exposed  or  not  to  ACS.  For  the  entire  study  popula-
tion,  there  was  no  cost  reduction  with  statistical  signiﬁcance
between  the  groups,  although  an  absolute  reduction  of
14--37%  between  the  different  cost  components  in  patients
receiving  ACS  was  observed.  At  the  analysis  of  preterm
infants  that  were  discharged  alive,  the  group  exposed  to
ACS  showed  a  reduction  of  24--47%  in  the  various  cost  com-
ponents,  with  statistical  signiﬁcance  for  the  respiratory  and
v
h
trug  components  and  signiﬁcant  decrease  in  hospital  length
f  stay.
The  group  of  newborns  with  birthweight  <1500  g,  also
onsidering  only  the  survivors,  beneﬁted  the  most  from  ACS
dministration,  with  signiﬁcant  reduction  in  all  cost  compo-
ents,  ranging  from  30%  to  50%,  with  a  decrease  of  36%  in
he  total  cost  (p  =  0.008).  For  the  group  of  neonates  with  GA
30  weeks  and  survivors,  a  signiﬁcant  reduction  of  some  of
he  cost  components  and  decrease  in  the  total  cost  of  38%
p  =  0.008)  were  observed,  accompanied  by  a  reduction  of
9%  in  days  of  hospitalization  in  the  NICU  (p  =  0.011).
iscussion
he  results  of  this  study  showed  a  signiﬁcant  reduction  in
everal  components  of  hospital  costs  of  preterm  infants  sub-
itted  to  ACS  therapy  in  Brazil,  which  are  more  evident  in
hose  who  were  discharged  alive,  with  birth  weight  <1500  g,
nd/or  GA  <30  weeks.  It  is  noteworthy  that,  from  a  clinical
oint  of  view,  preterm  infants  exposed  to  ACS,  when  com-
ared  to  those  who  were  not,  had  less  need  for  resuscitation
n  the  delivery  room,  lower  SNAPPE  II,18 and  less  need  for
echanical  ventilation,  similar  to  the  results  reported  to
ate  for  Brazilian  neonates.19
Therefore,  this  study,  a  pioneer  in  a  developing  coun-
ry  such  as  Brazil,  reinforces  the  WHO  guidelines  in  its  aim
o  reduce  neonatal  mortality,  demonstrating  the  beneﬁts  of
niversal  ACS  for  pregnant  women  at  risk  for  preterm  deliv-
ry,  now  considering  the  ﬁnancial  aspects  and  decrease  in
ealthcare  costs.
For  four  decades,  ACS  therapy  for  women  at  risk  of
reterm  delivery  has  been  recommended  as  one  of  the  most
ffective  interventions  to  reduce  neonatal  mortality  and
orbidity.5,10 Considering  the  previously  demonstrated  ben-
ﬁts,  not  using  ACS  is  considered  bad  practice  in  developed
ountries.  Therefore,  this  study  had  to  be  retrospective,
ocusing  on  the  use  of  healthcare  resources  and  hospital
osts.With  advances  in  neonatal  intensive  care,  preterm  sur-
ival  is  increasing,  albeit  accompanied  by  an  increase  in
ospital  costs.  Petrous  et  al.20 retrieved  19  publications
hat  analyzed  the  initial  costs  of  hospitalization  of  preterm
28  Ogata  JF  et  al.
Table  2  Morbidity  of  newborns  exposed  to  antenatal  corticosteroids  (ACS)  or  not,  expressed  in  numbers  (%)  and  relative  risk
with 95%conﬁdence  interval  (95%  CI).
With  ACS
n  =  170
Without  ACS
n  =  41
Relative  risk
(95%  CI)
p
Advanced  resuscitationa 27  (16%)  14  (34%)  0.46  (0.26--0.80)  0.007
SNAPPE II  >  40  14  (8%)  8  (19%)  0.42  (0.18--0.93)  0.033
RDS 90  (53%)  27  (66%)  0.80  (0.61--1.04)  0.135
Surfactant use 72  (42%) 24  (58%) 0.72  (0.52--0.98) 0.062
Mechanical  ventilation 90  (53%) 29  (70%) 0.74  (0.58--0.95) 0.039
Apnea 60  (35%) 16  (39%) 0.40  (0.58--1.39) 0.655
O2 at  36  weeks  24  (14%)  9(22%)  0.64  (0.32--1.27)  0.215
PDA 48  (28%)  13  (32%)  0.89  (0.52--1.48)  0.660
Surgical PDA  13  (8%)  4  (10%)  0.78  (0.26--2.27)  0.656
Blood transfusion  52  (30%)  19  (46%)  0.66  (0.44--0.98)  0.055
Clinical late-onset  sepsis  38  (22%)  8  (19%)  1.14  (0.57--2.26)  0.693
PIVH of  any  grade  84  (49%)  25  (60%)  0.81  (0.60--1.08)  0.183
PIVH III  and  IV  13  (8%)  7  (22%)  0.34  (0.16--0.75)  0.007
Periventricular  leukomalacia  3  (1.8%)  2  (4.9%)  0.36  (0.06--2.09)  0.250
ROP 35  (20%)  12  (29%)  0.70  (0.40--1.23)  0.230
ROP requiring  Laser  5(2.9%)  1  (2.4%)  1.20  (0.14--10)  0.670
Death 14  (8%)  5  (12%)  0.67  (0.25--1.76)  0.298
SNAPPEII, Score for Neonatal Acute Physiology Perinatal Extension II; RDS, respiratory distress syndrome; PDA, Patent ductus arteriosus;
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TPIVH, peri-intraventricular hemorrhage; ROP, Retinopathy of prem
a Advanced resuscitation: need for intubation and/or cardiac m
nfants  and  observed  huge  differences  in  cost  estimates
etween  the  studies,  making  comparisons  difﬁcult.  The
uthors  provide  a  number  of  explanations  for  this  variabil-
ty,  emphasizing  the  difference  between  the  time  when
he  studies  were  conducted  and  geographic  diversity,  which
ay  reﬂect  variations  in  medical  practices  and  healthcare
rganizations.  Nonetheless,  there  is  a  consistent  inverse
ssociation  between  hospitalization  costs  and  GA  or  birth-
eight,  similar  to  the  results  obtained  in  the  present  study.
In  that  review,  the  initial  costs  of  hospitalization  were
hown  to  be  related  to  preterm  mortality,  being  higher
mong  the  survivors.  Thus,  it  was  decided  that  the
resent  study  would  make  separate  analyses  for  the  entire
i
d
1
c
Table  3  Average  cost  in  US  dollars,  subdivided  among  its  ﬁve  co
risk, with  daily  costs  for  the  entire  study  population,  for  those  that
gestational age  ranges.
Patients  n  Cost  (U
Resp.  Med.  Lab.  Exams  
Entire  population  211  520  244  188  90  
Survivors 192  494  226  183  92  
Birth weight
<1000  g  33  1237  409  328  169  
<1500 g  128  670  282  224  109  
GA
26--27 weeks  22  1609  612  427  196  
28--29 weeks  48  735  362  236  117  
30 weeks  69  292  149  145  72  
32 weeks 53  142  115  101  55  
GA, gestational age; Resp, respiratory costs; Med, medication costs; Lab
Daily, daily hospital rate; ICU days, days of hospitalization in intensiveity.
e and/or medications in the delivery room.
opulation  and  for  the  survivors,  taking  into  account  the
orbidity  and  resource  utilization  during  hospital  stay.
Regarding  the  difference  between  the  several  hospi-
al  cost  components,  it  was  observed  that  wages  and
ndirect  costs  accounted  for  76%  of  the  total  costs,  and  the
irect  costs,  for  24%;  the  latter  were  divided  into  respiratory
osts,  25%;  pharmacy,  12%;  radiology,  5%;  laboratory,  9%;
nd  others  (nutrition,  procedures,  blood  therapy,  etc.),  49%.
hese  results  are  similar  to  those  obtained  when  analyz-
ng  25  units  of  the  Vermont  Oxford  network,  which  collects
ata  on  preterm  infants  whose  birth  weight  is  lower  than
500  g:  accommodation  costs,  which  include  salaries  and
osts  on  equipment  and  daily  rates,  accounted  for  72%  of
mponents,  days  of  intensive  care  unit  (ICU)  stay  and  medium
 were  discharged  alive  and  according  to  different  weight  and
SD)  Days  Daily  cost
Daily  hospital  rate  Total  ICU  MR
6618  8698  21  25  188
7036  9065  21  17  238
12,960  17,076  42  48  189
8618  11,189  27  33  186
14,855  20,150  59  45  193
9479  12,369  28  38  187
5596  7075  17  22  181
3819  4739  10  17  175
, laboratory costs; Exams, examination costs, except laboratory;
 care unit; MR days, days of hospitalization at medium risk.
Antenatal
 corticosteroids
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 cost
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Table  4  Average  cost  in  US  dollars,  subdivided  among  its  ﬁve  components,  days  of  intensive  care  unit  (ICU)  stay  and  medium  risk  for  all  patients,  for  those  that  were  discharged
alive, according  to  different  weight  and  gestational  age  ranges,  classiﬁed  according  to  exposure  to  antenatal  corticosteroids  (ACS)  or  not.
Patients n  Cost  Days
Resp. Med.  Lab  Exams  Daily  Total ICU  ICN
All  patients With  ACS 170  464  225  182  85  6258  8206  19  24
Without ACS 41  748  321  231  111  8110  10,736  27  29
Cost reduction 37% 30% 14% 23% 23% 23% 30% 17%
p  0.087 0.047 0.190 0.427 0.512 0.638 0.07 0.148
Survivors With ACS 156  423  199  173  84  6549  8383  19  26
Without ACS 36  801  346  227  123  9149  12,023  31  33
Cost reduction 47% 42% 24% 45% 28% 30% 38% 21%
p  0.043 0.019 0.082 0.098 0.131 0.150 0.015 0.05
<1500 g With  ACS 104  562  240  207  98  7871  10,121  24  31
Without ACS 24  1136  464  297  159  11,851  15,820  41  42
Cost reduction 50% 48% 30% 38% 33% 36% 41%  26%
p 0.005 0.004 0.005 0.006 0.009 0.008  0.122  0.021
<30 weeks With  ACS  55  792  328  261  120  9859  12,748  29  40
Without ACS  14  1629  637  374  213  15,224  20,688  57  49
Cost reduction  51%  48%  30%  43%  35%  38%  49%  18%
p 0.011  0.182  0.071  0.002  0.007  0.008  0.011  0.105
>30 weeks With  ACS  100  217  128  96  64  4723  5962  14  19
Without ACS  22  273  162  133  65  5283  6508  13  23
Cost reduction  20%  20%  7%  2%  10%  8%  7%  17%
p 0.317  0.044  0.349  0.675  0.714  0.775  0.899  0.317
Resp, respiratory costs; Med, medication costs; Lab, laboratory costs; Exams, examination costs, except laboratory; Daily, daily hospital rate; ICU days, days of hospitalization in intensive
care unit; ICN, intermediate care nursery.
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10  
he  total  cost,  while  the  direct  costs  amounted  to  28%  (res-
iratory,  22%;  laboratory,  24%;  radiology,  7%;  pharmacy,  16%;
nd  others,  31%).21
Some  Brazilian  publications  have  analyzed  the  cost  of
reating  preterm  infants.  In  2011,  Desgualdo  et  al.22 eval-
ated  hospital  costs  for  newborns  with  22  to  36  weeks  GA
ho  were  born  in  a  referral  hospital  in  São  Paulo,  Brazil.
he  authors  showed  that  the  mean  cost  per  day  for  preterm
nfants  whose  weight  was  <1000  g  was  USD  115.00.
More  recently,  Mwamakamba  et  al.23 estimated  the  direct
ospital  costs  of  84  preterm  infants  with  22--36  weeks  GA,
orn  to  adolescent  mothers  in  a  tertiary  public  hospital  in
ão  Paulo,  Brazil.  In  that  study,  the  highest  cost  compo-
ent  was  hospital  services  (72%);  the  mean  cost  for  those
eighing  less  than  1000  g  was  USD  8930.00,  with  a  mean
aily  cost  of  USD  157.00.  Despite  the  different  methodol-
gy,  the  daily  cost  value  for  preterm  infants  weighing  less
han  1000  g  found  in  the  present  study  was  estimated  at
SD  189.00,  a  value  comparable  to  that  described  by  Mwa-
akamba  et  al.,23 especially  when  considering  the  fact  that
hose  authors  did  not  consider  indirect  hospital  costs,  which
ay  correspond  to  16%  of  the  total  cost.
There  are  a  few  publications  in  the  literature  showing  the
mpact  of  ACS  on  cost  reduction.  The  ﬁrst  meta-analysis  con-
ucted  by  Crowley  et  al.24 in  1990  mentions  a  decrease  of
SD  17,300.00  in  mean  hospital  costs  associated  with  ante-
atal  corticosteroid  therapy,  based  on  the  ﬁndings  of  a  single
tudy.  In  1991,  Mugford  estimated  a  decrease  in  hospital
osts  of  patients  with  ACS,  taking  as  reference  the  cost  of
are  for  patients  with  and  without  respiratory  distress  syn-
rome.  The  use  of  ACS  for  pregnant  women  under  35  weeks
estation  would  reduce  the  mean  cost  per  infant  by  10%  and
he  mean  cost  per  survivor  by  14%.10
The  study  by  Carlan  et  al.25 estimated  a  reduction  of
esources  associated  with  ACS,  with  a  decrease  of  seven
ays  in  hospital  length  of  stay  and  of  USD  5000.00  in  costs.
ased  on  the  study  by  Simpson  &  Lynch,12 the  cost  reduc-
ion  estimate  promoted  by  ACS  was  19%.  The  results  of  the
resent  study  showed  a  reduction  in  hospital  costs  asso-
iated  with  antenatal  corticosteroids  ranging  from  23%  to
8%,  depending  on  the  weight  and  GA,  which  are  consid-
rable  values  that  must  be  considered  in  an  attempt  to
xpand  the  prescription  of  ACS  to  Brazilian  pregnant  women
t  risk  of  premature  birth.  Considering  the  national  sce-
ario,  where  approximately  40,000  preterm  infants  with
irth  weight  <1500  g  are  born  annually,26 and  based  on  a
ost  difference  of  USD  6000  found  in  this  study  among
ery-low  birth  weight  neonates  exposed  or  not  to  ACS,
 decrease  in  costs  of  approximately  230  million  dollars
 year  can  be  estimated,  if  the  antenatal  medication  was
dministered  to  95%  of  pregnant  women  with  threatened
abor.
It  is  worth  mentioning  the  study’s  limitations  regard-
ng  cost  estimates,  highlighting  the  fact  that  these  data
re  from  a  single  tertiary  and  teaching  hospital,  which
akes  it  difﬁcult  to  compare  it  with  non-university  and/or
maller  hospitals;  the  lack  of  a  single  cost  estimate  sys-
em  among  Brazilian  public  hospitals;  and  the  small  sample
f  patients,  particularly  the  lower  GA  groups  that  did  not
eceive  ACS.
However,  regarding  costs,  it  can  be  stated  that  there  is  a
uge  variation  in  the  data  analysis  methods  reported  in  the
1Ogata  JF  et  al.
iterature20 and  the  objective  was  to  attain  an  approxima-
ion  of  hospital  costs  to  compare  the  newborns  exposed  to
CS  or  to  those  who  were  not  exposed.  Despite  these  lim-
tations,  it  was  a  pioneering  study  in  Brazil,  comparing  the
conomic  impact  of  antenatal  medication  according  to  WHO
uidelines  that  encourage  the  use  of  simple  and  effective
echnologies  in  low  and  middle-income  countries  to  reach
he  global  aim  of  reducing  neonatal  mortality  by  the  year
035.
It  can  be  concluded  that  the  use  of  ACS  is  a simple  mea-
ure  that  contributes  to  reduce  prematurity  complications
nd  the  use  of  health  resources,  reducing  hospital  costs  for
reterm  infants  with  GA  between  26  and  32  weeks  in  Brazil.
his  effect  is  predominant  among  those  weighing  <1500  g
nd/or  under  30  weeks  GA  who  survive  until  hospital  dis-
harge.
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